Skip to content

Study · Non-randomized trial · n = 728 · 2010

10 results

[Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten].

Voznesenskaia TG, Fokina NM, Iakhno NN

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2010Cited by 1 (Europe PMC)

PMID21322821 (opens in a new tab)PepBankPUB-21322821
Publisher pageAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome and asthenia, the CGI-S responder proportion during ladasten treatment was 76.0%.

    In plain wordsIn patients with psychoautonomic syndrome and asthenia, 76.0% responded on CGI-S during ladasten treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableCGI-S responders
    Study

    n = 728

    Outcome group
    Overall treatment effect · Mental health and mood
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Measurements

    Responders
    76%
    CGI-S

    Source sentences

    Summary
    The percentage of responders was 76.0% on the CGI-S and 90.8% on the CGI-I.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome and asthenia, the CGI-I responder proportion during ladasten treatment was 90.8%.

    In plain wordsIn patients with psychoautonomic syndrome and asthenia, 90.8% responded on CGI-I during ladasten treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableCGI-I responders
    Study

    n = 728

    Outcome group
    Overall treatment effect · Mental health and mood
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Measurements

    Responders
    90.8%
    CGI-I

    Source sentences

    Summary
    The percentage of responders was 76.0% on the CGI-S and 90.8% on the CGI-I.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome, ladasten showed an antiasthenic effect on day 3 that persisted one month after treatment withdrawal.

    In plain wordsIn patients with psychoautonomic syndrome, ladasten reduced asthenic symptoms from day 3, with effects lasting one month after treatment withdrawal.

    Peptide
    Bromantane
    Outcome
    DecreaseAsthenic symptoms
    Study

    n = 728

    Outcome group
    Fatigue · Whole body
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Source sentences

    Summary
    The antiasthenic effect of ladasten was seen on day 3 and remained during one month after the withdrawal of therapy.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome, the study reported clinical efficacy of ladasten for anxiety-depressive spectrum disorders.

    In plain wordsIn patients with psychoautonomic syndrome, the study reported that ladasten improved anxiety-depressive disorders.

    Peptide
    Bromantane
    Outcome
    DecreaseAnxiety-depressive spectrum disorders
    Study

    n = 728

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Source sentences

    Summary
    We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome, the study reported clinical efficacy of ladasten for autonomic dystonia.

    In plain wordsIn patients with psychoautonomic syndrome, the study reported that ladasten improved autonomic dystonia.

    Peptide
    Bromantane
    Outcome
    DecreaseAutonomic dystonia
    Study

    n = 728

    Outcome group
    Autonomic function · Nervous system and cognition
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Source sentences

    Summary
    We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome, the study reported clinical efficacy of ladasten for sleep disorders.

    In plain wordsIn patients with psychoautonomic syndrome, the study reported that ladasten improved sleep disorders.

    Peptide
    Bromantane
    Outcome
    DecreaseSleep disorders
    Study

    n = 728

    Outcome group
    Sleep · Sleep
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Source sentences

    Summary
    We determined clinical efficacy of ladasten in regard to anxiety-depressive spectrum disorders, autonomic dystonia, sleep disorders.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with psychoautonomic syndrome, quality of life increased significantly after ladasten treatment and remained increased after withdrawal.

    In plain wordsIn patients with psychoautonomic syndrome, quality of life increased during ladasten treatment and remained higher after treatment ended.

    Peptide
    Bromantane
    Outcome
    IncreaseQuality of life
    Study

    n = 728

    Outcome group
    Quality of life · Whole body
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Ladasten therapy led to the significant increase of quality of life, which was seen not only after the end of therapy, but after the withdrawal of the drug.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  8. 08HumanNon-randomized trialSafety outcome

    In patients with psychoautonomic syndrome, adverse effects occurred in 3% during ladasten therapy.

    In plain wordsIn patients with psychoautonomic syndrome, 3% had adverse effects during ladasten treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableAdverse effects
    Study

    n = 728

    Outcome group
    Adverse events · Whole body
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Measurements

    Adverse effects
    3%
    ladasten-treated patients

    Source sentences

    Summary
    Adverse effects were observed only in 3% of patients, the therapy was discontinued in 0.8%.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  9. 09HumanNon-randomized trialSafety outcome

    In patients with psychoautonomic syndrome, ladasten therapy was discontinued in 0.8%.

    In plain wordsIn patients with psychoautonomic syndrome, 0.8% discontinued ladasten treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableTreatment discontinuation
    Study

    n = 728

    Outcome group
    Adverse events · Whole body
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Measurements

    Discontinuation
    0.8%
    ladasten-treated patients

    Source sentences

    Summary
    Adverse effects were observed only in 3% of patients, the therapy was discontinued in 0.8%.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.
  10. 10HumanNon-randomized trialSafety outcome

    In patients with psychoautonomic syndrome, no serious adverse effects occurred during ladasten therapy.

    In plain wordsIn patients with psychoautonomic syndrome, the study found no serious adverse effects during ladasten treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableSerious adverse effects
    Study

    n = 728

    Outcome group
    Adverse events · Whole body
    Studied dose
    50 to 100 mg daily · 28 daysAs given in this study (human).

    Source sentences

    Summary
    No serious adverse effects were found.
    1 context sentence
    Summary · context
    The data on 728 patients with psychoautonomic syndrome (91.6% of the total sample) were available for statistical analysis. All patients suffered from asthenic disorders. The duration of treatment with ladasten in daily dose from 50 to 100 mg was 28 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.